



THE UNIVERSITY *of* EDINBURGH

## Edinburgh Research Explorer

### Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome

**Citation for published version:**

Fox, KAA, Dabbous, OH, Goldberg, RJ, Pieper, KS, Eagle, KA, Van de Werf, F, Avezum, A, Goodman, SG, Flather, MD, Anderson, FA & Granger, CB 2006, 'Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE)', *British Medical Journal (BMJ)*, vol. 333, no. 7578, pp. 1091.  
<https://doi.org/10.1136/bmj.38985.646481.55>

**Digital Object Identifier (DOI):**

[10.1136/bmj.38985.646481.55](https://doi.org/10.1136/bmj.38985.646481.55)

**Link:**

[Link to publication record in Edinburgh Research Explorer](#)

**Document Version:**

Publisher's PDF, also known as Version of record

**Published In:**

British Medical Journal (BMJ)

**General rights**

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

**Take down policy**

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact [openaccess@ed.ac.uk](mailto:openaccess@ed.ac.uk) providing details, and we will remove access to the work immediately and investigate your claim.



## Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE)

Keith A A Fox, Omar H Dabbous, Robert J Goldberg, Karen S Pieper, Kim A Eagle, Frans Van de Werf, Álvaro Avezum, Shaun G Goodman, Marcus D Flather, Frederick A Anderson Jr, Christopher B Granger, for the GRACE Investigators

### Abstract

**Objective** To develop a clinical risk prediction tool for estimating the cumulative six month risk of death and death or myocardial infarction to facilitate triage and management of patients with acute coronary syndrome.

**Design** Prospective multinational observational study in which we used multivariable regression to develop a final predictive model, with prospective and external validation.

**Setting** Ninety four hospitals in 14 countries in Europe, North and South America, Australia, and New Zealand.

**Population** 43 810 patients (21 688 in derivation set; 22 122 in validation set) presenting with acute coronary syndrome with or without ST segment elevation enrolled in the global registry of acute coronary events (GRACE) study between April 1999 and September 2005.

**Main outcome measures** Death and myocardial infarction.

**Results** 1989 patients died in hospital, 1466 died between discharge and six month follow-up, and 2793 sustained a new non-fatal myocardial infarction. Nine factors independently predicted death and the combined end point of death or myocardial infarction in the period from admission to six months after discharge: age, development (or history) of heart failure, peripheral vascular disease, systolic blood pressure, Killip class, initial serum creatinine concentration, elevated initial cardiac markers, cardiac arrest on admission, and ST segment deviation. The simplified model was robust, with prospectively validated C-statistics of 0.81 for predicting death and 0.73 for death or myocardial infarction from admission to six months after discharge. The external applicability of the model was validated in the dataset from GUSTO IIIb (global use of strategies to open occluded coronary arteries).

**Conclusions** This risk prediction tool uses readily identifiable variables to provide robust prediction of the cumulative six month risk of death or myocardial infarction. It is a rapid and widely applicable method for assessing cardiovascular risk to complement clinical assessment and can guide patient triage and management across the spectrum of patients with acute coronary syndrome.

### Introduction

Although patients with acute coronary syndrome share key pathophysiological mechanisms, they present with diverse clinical, electrocardiographic, and enzyme or marker characteristics

and experience a wide range of serious cardiovascular outcomes.<sup>1 2</sup> Estimated risk, based on clinical characteristics, is challenging and imprecise, yet risk assessment is needed to guide triage and key management decisions. Regulatory authorities such as the National Institute for Health and Clinical Excellence (NICE) and guideline groups recommend treatments according to specific clinical and risk groupings, and trials show that certain benefits may be predominantly or exclusively restricted to higher risk patients with coronary syndrome.<sup>2-4</sup> Binary methods of stratifying risk (for example, normal or raised troponin concentration or abnormal or normal findings on electrocardiography) lack sufficient precision.<sup>5-11</sup> To provide more accurate prognostic information, and to target treatment more appropriately, more precise yet user friendly risk stratification is required. To ensure general applicability, risk stratification methods should be derived from unrestricted populations that are representative of patients with acute coronary syndrome in the real world<sup>12</sup> and should use widely available clinical variables.

The large multinational observational global registry of acute coronary events (GRACE) has been used to derive regression models to predict death in hospital<sup>13</sup> and death after discharge<sup>14</sup> in patients with acute coronary syndrome. However, a comprehensive risk model is required to predict the cumulative risk of death and death or myocardial infarction during the high risk first six months after initial presentation with acute coronary syndrome, the period when most complications occur.<sup>15 16</sup> Because triage and management decisions are required within the first hours or days after initial presentation we derived a risk tool from characteristics of patients with acute coronary syndrome at initial presentation.

### Methods

#### GRACE methods and design

Full details of the GRACE rationale and methods have been published elsewhere.<sup>17 18</sup> The registry was designed to reflect an unbiased population of patients with acute coronary syndrome in 94 hospitals in 14 countries. All cases were assigned to one of the following categories: ST segment elevation myocardial infarction, non-ST elevation myocardial infarction, or unstable angina (see appendix on bmj.com for inclusion criteria and



Full details of inclusion criteria and standard definitions can be found on [bmj.com](http://bmj.com).

standard definitions). Trained coordinators collected data using standardised case report forms.

### Statistical methods

We used two primary end points: all cause death or the composite measure of death or non-fatal myocardial infarction during admission to hospital or after discharge (presentation to six months).

We have summarised the distributions of continuous variables with medians and 25th and 75th centiles and reported the categorical variables as frequencies and percentages. Events that occurred after six months were censored. Table 1 shows the variables included in the analysis from hospital admission to six month follow-up. We used a Cox regression model to compute crude hazard ratios and 95% confidence intervals to examine the individual relation between each predictor and death and death or myocardial infarction during follow-up (0 to 6 months).

We entered all demographic and clinical variables identified by the crude regression analysis into the stepwise multiple Cox regression (backward) analysis to produce final models for predicting death and death or myocardial infarction. Only those variables associated with an  $\alpha \leq 0.05$  were retained; all variables in the final model met the assumptions for proportional hazards. No imputation was performed in these final models. Imputation was tested but did not influence the identification of multivariable predictors or the discriminative power of the model for predicting death.<sup>13</sup> The discriminative power of the final models was assessed by the mean of the area under the receiver operating characteristic (ROC) curve (C-statistic). The curve is a measure of the discriminating ability of the risk model and is a plot of sensitivity versus 1 – specificity. Accuracy of calibration was evaluated by plotting the predicted versus the observed mortality according to population tenths of predicted risk. The model was tested prospectively in a separate dataset in GRACE ( $n = 22\ 122$ ) and also in an independent external dataset, the GUSTO IIb (global use of strategies to open occluded coronary arteries IIb) dataset,<sup>19</sup> comprising the entire spectrum of patients with acute coronary syndrome (12 142 patients, 4131 with ST elevation myocardial infarction, 8011 with non-ST elevation myocardial infarction). The analysis was performed with SAS software package (version 8.2, SAS Institute, Cary, NC) and S-Plus (MathSort, Seattle, WA).

## Results

### Study population


The derivation population comprised 26 267 patients with suspected acute coronary syndrome enrolled between 1 April 1999 and 30 September 2002. We excluded patients found to have a non-cardiac or non-acute coronary cardiac diagnosis (fig 1). We also excluded patients transferred into a study hospital because they lacked some baseline information and their inclusion may also have led to bias because of morbidity associated with the indications for transfer. The study population therefore comprised 21 688 patients of whom 19 931 were alive at six month follow-up.

A total of 1757 (9.1%) deaths occurred, 1046/21 573 in hospital (4.9% among patients with a diagnosis of acute coronary syndrome on admission) and 711/15 265 during the period after discharge (4.7%). We had no information on mortality (in hospital or after discharge) for 51 patients. In the derivation set, 3110 (15.8%) patients died ( $n = 1757$ ) or experienced a non-fatal myocardial infarction ( $n = 1353$ ) between presentation and six month follow-up.

**Table 1** Factors associated with death and death or myocardial infarction (MI) from hospital admission to six month follow-up (hazard ratios and 95% confidence intervals)

Predictors	$\chi^2$	Death model	$\chi^2$	Death/MI model
<b>Demographics</b>				
Age (per 10 year increase)	915.3	1.34 (1.31 to 1.36)	345.4	1.13 (1.11 to 1.15)
Male	73.9	0.7 (0.60 to 0.72)	15.5	0.9 (0.80 to 0.93)
Weight (per 1 kg increase)	133.2	0.98 (0.97 to 0.98)	30.9	0.99 (0.990 to 0.995)
Height (per 1 cm increase)	59.0	0.98 (0.97 to 0.98)	21.1	0.99 (0.987 to 0.995)
<b>Medical history</b>				
Angina	7.5	0.9 (0.80 to 0.96)	17.2	0.9 (0.80 to 0.92)
Smoking	65.2	0.7 (0.61 to 0.74)	34.1	0.8 (0.75 to 0.87)
Stroke	69.2	1.8 (1.56 to 2.10)	36.5	1.4 (1.26 to 1.58)
Diabetes	61.2	1.5 (1.36 to 1.67)	29.4	1.2 (1.15 to 1.35)
Coronary artery disease	13.4	0.8 (0.72 to 0.91)	78.1	0.7 (0.63 to 0.74)
Myocardial infarction	18.5	1.2 (1.13 to 1.37)	1.0	1.0 (0.96 to 1.12)
Congestive heart failure	373.6	3.0 (2.66 to 3.32)	142.8	1.8 (1.65 to 2.00)
Peripheral vascular disease	91.0	1.9 (1.64 to 2.12)	33.7	1.4 (1.23 to 1.52)
Hypertension	30.8	1.3 (1.20 to 1.47)	4.0	1.1 (1.00 to 1.16)
Hyperlipidaemia	109.6	0.6 (0.52 to 0.64)	104.9	0.7 (0.63 to 0.73)
Atrial fibrillation	152.8	2.3 (2.00 to 2.60)	46.9	1.5 (1.33 to 1.66)
Renal dysfunction	129.5	2.2 (1.90 to 2.50)	25.8	1.3 (1.20 to 1.50)
PCI	42.8	0.6 (0.49 to 0.68)	67.4	0.6 (0.55 to 0.69)
CABG	3.1	0.9 (0.75 to 1.02)	22.6	0.8 (0.68 to 0.85)
Positive exercise tolerance test	22.1	0.6 (0.54 to 0.77)	37.3	0.7 (0.58 to 0.75)
Bleeding	27.1	2.1 (1.60 to 2.77)	4.3	1.3 (1.02 to 1.79)
Delay in admission	0.1	1.0 (1.00 to 1.00)	0.9	1.0 (1.00 to 1.00)
<b>Presentation characteristics</b>				
Pulse	286.8	1.02 (1.01 to 1.02)	177.4	1.01 (1.009 to 1.012)
Diastolic blood pressure	261.2	0.98 (0.98 to 0.98)	66.9	0.99 (0.989 to 0.993)
Systolic blood pressure	278.2	0.99 (0.98 to 0.99)	134.5	0.99 (0.991 to 0.994)
Killip class	1318.5	2.6 (2.47 to 2.74)	658.7	1.9 (1.80 to 1.98)
Cardiac arrest	306.6	5.5 (4.52 to 6.62)	230.6	3.8 (3.21 to 4.50)
Initial cardiac markers	246.1	2.2 (1.97 to 2.40)	375.7	2.1 (1.94 to 2.24)
Initial serum creatinine	334.2	1.3 (1.25 to 1.32)	125.1	1.2 (1.15 to 1.21)
<b>Findings on electrocardiography</b>				
ST elevation	112.3	1.7 (1.52 to 1.84)	276.6	1.8 (1.72 to 1.98)
ST depression	95.8	1.6 (1.47 to 1.78)	95.5	1.4 (1.34 to 1.54)
ST segment deviation	215.1	2.2 (1.98 to 2.45)	294.2	2.0 (1.84 to 2.14)
T wave inversion or pseudonormalisation	31.8	0.7 (0.65 to 0.81)	34.6	0.8 (0.72 to 0.85)
ST elevation anterior	105.8	1.8 (1.56 to 1.97)	138.3	1.7 (1.52 to 1.79)
ST elevation inferior	13.0	1.2 (1.10 to 1.40)	88.4	1.5 (1.37 to 1.62)
ST depression anterior	58.0	1.6 (1.39 to 1.75)	75.4	1.5 (1.35 to 1.60)
ST depression inferior	16.3	1.4 (1.17 to 1.59)	24.9	1.3 (1.19 to 1.50)
No of leads with ST elevation	144.8	1.5 (1.37 to 1.56)	284.4	1.5 (1.44 to 1.58)
No of leads with ST depression	97.8	1.4 (1.28 to 1.44)	86.0	1.2 (1.19 to 1.30)
Any significant Q wave	63.6	1.5 (1.37 to 1.67)	40.4	1.3 (1.19 to 1.39)
Left bundle branch block	82.7	2.1 (1.79 to 2.47)	32.2	1.5 (1.30 to 1.70)
Right bundle branch block	56.4	1.9 (1.58 to 2.17)	18.2	1.3 (1.17 to 1.54)
Other changes	168.8	2.1 (1.89 to 2.33)	84.0	1.5 (1.40 to 1.68)
<b>Previous use of medical therapy</b>				
Anti-arrhythmic drugs	16.9	1.7 (1.30 to 2.11)	0.1	1.0 (0.83 to 1.27)
Oral/topical nitrates	17.2	1.3 (1.13 to 1.39)	3.0	0.9 (0.85 to 1.01)
Aspirin	4.1	0.9 (0.82 to 0.99)	41.8	0.8 (0.73 to 0.84)
ACE inhibitors	20.5	1.3 (1.15 to 1.41)	0.01	1.0 (0.92 to 1.08)
Calcium channel blocker	10.1	1.2 (1.07 to 1.35)	1.0	1.0 (0.87 to 1.04)
Statins	55.8	0.6 (0.52 to 0.68)	89.8	0.6 (0.57 to 0.69)

PCI=percutaneous coronary intervention; CABG=coronary artery bypass grafting; ACE=angiotensin converting enzyme.



**Fig 1** GRACE study profile (derivation set of patients)

Early risks were highest for patients with ST segment elevation myocardial infarction but by six months the risk of death was similar to those with non-ST segment elevation myocardial infarction (fig 2). Of those who survived to six months after discharge, 36.2% (258/711) presented with ST segment elevation myocardial infarction compared with 50.0% (880/1757) of those who died during admission or follow-up. Raised cardiac markers were detected in 35.0% (6883/19688) of those who survived compared with 53.2% (905/1701) of those who died.

### Validation population

The validation set comprised 22 122 patients enrolled in this multinational registry between 1 October 2003 and 30 September 2005. A total of 1730 (9.0%) patients died between hospital admission and six month follow-up, 948 in hospital (4.3% among patients with an admission diagnosis of acute coronary syndrome) and 782 (5.4%) after discharge. No information on mortality was available for 38 patients. In total, 2720 patients died (n=1730) or experienced a non-fatal myocardial infarction (n=990) between presentation and six month follow-up.


### Predictors of mortality

From admission to six month follow-up, Killip class<sup>20</sup> and advanced age were the most powerful predictors of death in the univariable analysis (table 1). Table 1 also shows the other baseline characteristics and clinical parameters that predicted death or death or myocardial infarction.

After multivariable analysis, the highest hazard ratios for death were cardiac arrest on admission and increasing age. These two key prognostic factors were closely followed by raised cardiac markers or enzyme activity and ST segment deviation (table 2).

### Risk models predicting death and death or myocardial infarction

The risk model comprises 14 predictors of death and 12 predictors of death or myocardial infarction. The predictive accuracy of the model was good, with C-statistics of 0.82 for death in hospital and 0.70 for death or myocardial infarction in hospital (table 3). Nine factors independently predicted death and the combined end point in the period from admission to six months after discharge: age, congestive heart failure, peripheral vascular disease, systolic blood pressure, Killip class, initial serum creatinine concentration, positive initial cardiac markers, cardiac arrest on admission, and number of leads with ST deviation. The



**Fig 2** Overall risk of death in hospital, from hospital admission to six months after discharge (patients separated into unstable angina, non-ST segment elevation myocardial infarction, and ST segment elevation myocardial infarction), and from hospital discharge to six months

highest hazard ratio for adverse outcome was for cardiac arrest (tables 1 and 2).

### Prospective and external validation of the GRACE risk score

When we tested the risk model in the prospective validation set, it had excellent predictive accuracy for death (C-statistic=0.81, simplified model) and death or myocardial infarction (C-statistic=0.73). The predictive accuracy was maintained across the acute coronary syndrome subgroups (table 3).

We validated the model externally using the GUSTO IIb dataset of 12 142 patients with acute coronary syndrome. There was excellent discrimination despite the fact that one of the key parameters was not recorded in GUSTO IIb (cardiac arrest). The C-statistic for the death model in all patients was 0.82 (C-statistics=0.80 for ST segment elevation myocardial infarction and 0.76 for non-ST segment elevation myocardial infarction).

### Development of a simplified nomogram for clinical application

We reduced the overall models to include the most important variables that contained most (>90%) of the predictive informa-



**Table 2** Final risk models predicting death and death or myocardial infarction from hospital admission to six month follow-up (hazard ratios and 95% confidence intervals)

Predictors	$\chi^2$	Death model	$\chi^2$	Death/MI model
Age (per 10 year increase)	505.7	1.8 (1.68 to 1.84)	176.3	1.25 (1.21 to 1.29)
Medical history:				
Congestive heart failure	34.2	1.5 (1.32 to 1.73)	22.1	1.3 (1.17 to 1.45)
Hypertension	8.8	1.2 (1.05 to 1.33)		—
Peripheral vascular disease	21.8	1.4 (1.21 to 1.62)	10.5	1.2 (1.08 to 1.36)
PCI	8.3	0.8 (0.64 to 0.93)		—
Presentation characteristics:				
Pulse (per 30 beats/min increase)	44.3	1.2 (1.16 to 1.31)		—
Systolic blood pressure (per 20 mm Hg decrease)	152.0	1.2 (1.22 to 1.30)	52.9	1.1 (1.07 to 1.13)
Killip class <sup>20</sup> (per level increase)	142.8	1.5 (1.41 to 1.62)	126.2	1.4 (1.30 to 1.46)
Initial serum creatinine (per 88 $\mu\text{mol/l}$ * increase)	135.3	1.2 (1.19 to 1.29)	41.1	1.1 (1.08 to 1.16)
Initial cardiac markers or enzymes	63.0	1.6 (1.42 to 1.78)	184.3	1.7 (1.60 to 1.87)
Cardiac arrest	58.5	2.6 (2.00 to 3.32)	55.4	2.2 (1.76 to 2.63)
Findings on electrocardiography:				
ST segment deviation	46.8	1.6 (1.41 to 1.88)		—
Left bundle block branch	10.0	1.3 (1.10 to 1.60)		—
No of leads with ST segment elevation or depression	20.1	1.2 (1.10 to 1.33)	158.4	1.4 (1.34 to 1.49)
ST depression, anterior		—	36.2	1.3 (1.22 to 1.47)
ST depression, inferior		—	10.8	1.2 (1.09 to 1.40)
Other changes		—	7.2	1.1 (1.04 to 1.27)
Hosmer and Lemeshow goodness of fit test		0.30		0.42
C-statistic		0.82		0.70

PCI=percutaneous coronary intervention.

\*Equivalent to 1 mg/dl.

tion. This nomogram retained excellent discriminant characteristics based on eight variables and was used for the calculation of risk (fig 3).

## Discussion

The GRACE risk prediction tool (simplified nomogram) includes variables that are readily available to clinicians even in smaller community hospitals. It provides a novel and widely applicable method of assessing the cumulative six month risk of death and death or myocardial infarction across the spectrum of patients admitted to hospital with acute coronary syndrome. Accurate longer term assessment of risk is important because most cardiac ischaemic events occur within the first few weeks after initial presentation with acute coronary syndrome.<sup>15 16</sup> Our findings, based on 48 389 patients, support the validity of the GRACE models for mortality in hospital and after discharge,<sup>14</sup> which were derived from data from about 11 000 and 15 000 patients, respectively.

### The need for risk prediction in patients with acute coronary syndrome

In clinical practice, initial stratification of patients aims to identify those suitable for reperfusion therapy (on the basis of a clinical syndrome and ST segment elevation or other electrocardiographic markers of acute infarction). Binary approaches are

**Table 3** C-statistics for validation of the full model and the simplified model (as used for the nomogram) for all GRACE patients and for acute coronary syndrome subgroups

	All patients	STEMI	Unstable angina/ NSTEMI
<b>All GRACE patients</b>			
Death:			
Full model	0.82	0.82	0.81
Simplified model	0.81	0.82	0.79
Death or myocardial infarction:			
Full model	0.70	0.66	0.71
Simplified model	0.70	0.66	0.70
<b>Transferred patients</b>			
Death:			
Full model	0.83	—	—
Simplified model	0.83	—	—
Death or myocardial infarction:			
Full model	0.71	—	—
Simplified model	0.70	—	—
<b>Model validation*</b>			
Death:			
Full model	0.82	0.83	0.81
Simplified model	0.81	0.82	0.81
Death or myocardial infarction:			
Full model	0.73	0.73	0.73
Simplified model	0.73	0.73	0.73

STEMI=ST segment elevation myocardial infarction; NSTEMI=non-ST segment elevation myocardial infarction.

\*On subsequent patients with acute coronary syndrome (22 122 enrolled between 1 October 2003 and 30 September 2005).

commonly applied among others with acute coronary syndrome, but separating patients based on one or two characteristics may substantially overestimate or underestimate the risk of death or myocardial infarction. There is therefore a need for one predictive instrument that performs well in all patients with acute coronary syndrome.

Robust evidence and practice guidelines (including NICE) suggest that interventional and pharmacological therapies predominantly benefit patients at higher risk.<sup>2 3 21</sup> Despite the availability of such guidelines, identification of patients at high risk of cardiac ischaemic events remains challenging.<sup>22 23</sup> In addition, the triage of patients into high intensity care units (cardiac care units) is based predominantly on the criteria for reperfusion therapy rather than risk in the patient. For example, a 55 year old woman (blood pressure 142/80 mm Hg; heart rate 88 per minute) who presents with ST elevation and raised troponin concentration but without complications of a myocardial infarction

**Fig 3** GRACE risk calculator for death or myocardial infarction from admission to hospital to six months after discharge with the simplified model ([www.outcomes.org/grace](http://www.outcomes.org/grace))

**Table 4** Resolving intermediate risk (examples). Which patient has higher risk of death or death or myocardial infarction? Is most of risk in hospital or later?

Variable	Example 1	Example 2	Example 3
Sex	Female	Male	Female
Age (years)	49	60	62
Heart rate (bpm)	109	94	90
Systolic BP (mm Hg)	100	110	114
Creatinine ( $\mu\text{mol/l}$ )	104	71	106
Killip class	II	I	II
Electrocardiographic results	T wave inversion	Non-specific T wave changes	T wave t inversion
Troponin T ( $\mu\text{g/l}$ )	<0.1	1.5	2.0
Death in hospital (death at six months)	1% (2%)	2% (7%)	5% (12%)
Death or MI at six months	12%	22%	31%

BP=blood pressure; bpm=beats per minute; MI=myocardial infarction.

tion (normal creatinine concentration, no heart failure) has a probability of death of only 3% in the next six months. However, a 55 year old woman with non-ST segment elevation myocardial infarction (blood pressure 118/68; heart rate 92 per min) with mild heart failure and raised creatinine concentration has a six month risk of death of 16%. Without formal risk stratification, the second patient would probably be managed in a low intensity ward area and the management on discharge may not reflect the risk in the patient.

### Resolving intermediate risk

Despite similarities in key pathophysiological mechanisms, the characteristics on presentation of patients with acute coronary syndrome depend on the extent of the ischaemic territory (influenced by acute thrombotic risk) and previous risk features (such as older age, heart failure, and renal insufficiency). Whereas patients with high risk features, including cardiogenic shock and heart failure, are relatively straightforward to identify, most patients lie in the intermediate range and risk is less obvious (table 4). This intermediate range encompasses up to 10-fold differences in the risk of death. Binary approaches, including those that require separation of patients into high or low risk, are not accurate enough for most patients in the middle range.<sup>2-3</sup> We propose that an appropriate instrument for risk prediction needs to be applicable across the spectrum of acute coronary syndrome, should be derived from a representative and broadly based population, and needs to use variables that are readily available to most clinicians shortly after the patient arrives at hospital.

### How does the present model differ from previous methods of risk stratification?

Several other multivariable prognostic models have been developed,<sup>5-10 24-28</sup> most of which were derived from clinical trial databases or specific subgroups of patients with acute coronary syndrome. Patients with complications and comorbidity tend to be excluded from such trials, thus limiting applicability in clinical practice. Models developed from large claims databases are potentially subject to bias.<sup>8-11</sup> In contrast, the GRACE registry spans the spectrum of acute coronary syndrome and is based on an unselected contemporary population.

A C-statistic of less than 0.70 has been suggested to be of limited clinical value.<sup>12</sup> The TIMI (thrombolysis in myocardial infarction) model performs well in patients who are eligible for reperfusion therapy but is less effective in more general patients, including those who are ineligible for reperfusion (C-statistic=0.65).<sup>24</sup> An independent study suggests that the

unselected GRACE mortality model is superior to either the TIMI or the PURSUIT (platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression with eptifibatide) models.<sup>29</sup> We have shown that the cumulative (0 to six month) GRACE risk model performs well across the spectrum of acute coronary syndrome and has prospective and external validity. External validation with the GUSTO IIb dataset confirms the discriminant characteristics of the model when applied to patients with ST segment elevation myocardial infarction and those with non-ST segment elevation myocardial infarction. Although we excluded transferred patients from the derivation of this model (because such patients may lack data for several baseline characteristics), testing the model in the transfer dataset confirmed its applicability to such patients (C-statistic=0.83 for predicting death and 0.70 for predicting myocardial infarction, simplified model).

### Simplified risk calculation for clinical application

The simplified model includes most the predictive information: >92% of the total model  $\chi^2$  for death and >90% for death or myocardial infarction (fig 3). The GRACE risk calculator (fig 3) (available at [www.outcomes.org/grace](http://www.outcomes.org/grace)) can be used to derive a prognostic score and to estimate the risk of clinically important end points—death or the combined risk of death or myocardial infarction—in individual patients. For ease of use, this nomogram can be installed into a handheld device or personal computer (data entry takes about 30 seconds) and is also available as a score card.<sup>14</sup>

### Limitations

GRACE is designed to enrol an unselected and generalisable population of patients, though some participating centres are required to obtain informed consent from patients before enrolment. Therefore some patients who died early or who experienced major clinical complications immediately on arrival in hospital may be under-represented. The model may not be appropriate for stratifying low risk patients with non-specific chest pain without acute coronary syndrome, but such patients do not require the same therapeutic and management decisions as those with acute coronary syndrome.

We thank the physicians and nurses who participated in GRACE. The risk calculator is available together with further information about the project

### What is already known on this topic

Specific treatments are indicated in higher or lower risk patients with acute coronary syndrome

Conventional clinical assessment and binary methods for predicting risk based on results of electrocardiography and markers of injury are not sufficiently accurate

Previous risk models were based on subgroups of patients with acute coronary syndrome and were derived from large clinical trials or healthcare claims databases

### What this study adds

The GRACE risk tool can be used to predict the cumulative risk of death and death or myocardial infarction in the period from admission to hospital to six months after discharge

The tool is simple to apply, robust, externally validated, and applicable to patients across the complete spectrum of acute coronary syndrome

and the complete list of participants from [www.outcomes.org/grace](http://www.outcomes.org/grace). We thank Sophie Rushton-Smith for editorial services.

Contributors: KAAF, RJG, KAE, FVdeW, AA, SGG, FAA, and CBG were responsible for study concept and design. KAAF, KAE, FVdeW, AA, SGG, and CBG acquired the data. KAAF drafted the manuscript and is guarantor. All authors critically revised the manuscript for important intellectual content and approved the final version. OHD and KSP carried out statistical analyses.

Funding: The GRACE Registry is supported by an unrestricted educational grant from Sanofi-Aventis to the Center for Outcomes Research, University of Massachusetts Medical School. Sophie Rushton-Smith was funded by Sanofi-Aventis.

Competing interests: KAAF has received grant funding from the British Heart Foundation and his department is supported by the British Heart Foundation, Medical Research Council, Wellcome Trust, Sanofi-Aventis, Bristol-Myers Squibb, and MSD. KAE has received grants from Biosite, Bristol-Myers Squibb, Cardiac Sciences, Blue Cross Blue Shield of Michigan, Hewlett Foundation, Mardigian Fund, Sanofi-Aventis, Varbedian Fund, National Heart, Lung and Blood NIH, and Pfizer. FVdeW has received research grants from Boehringer Ingelheim, Sanofi-Aventis, Proctor and Gamble, Servier, Novartis, MSD, and Schering Plough. AA has received funding from Sanofi-Aventis, Population Health Research Institute, and Boehringer Ingelheim. SGG has received funding from AstraZeneca, Sanofi-Aventis, Boehringer Ingelheim, Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership, Hoffmann-La Roche Pharmaceuticals, Merck, Novartis, Pfizer, Sanofi-Synthelabo, Schering Corp, and Millennium Pharmaceuticals. MDF, FAA, CBG, and BK have all received funding from Sanofi-Aventis.

Ethical approval: Approval was obtained from local institutional review boards.

- 1 Van de Werf F, Ardissino D, Betriu A, Cokkinos DV, Falk E, Fox KA, et al. Management of acute myocardial infarction in patients presenting with ST-segment elevation. The task force on the management of acute myocardial infarction of the European Society of Cardiology. *Eur Heart J* 2003;24:28-66.
- 2 Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, et al. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. *J Am Coll Cardiol* 2000;36:970-1062.
- 3 Bertrand ME, Simoons ML, Fox KA, Wallentin LC, Hamm CW, McFadden E, et al. Management of acute coronary syndrome: acute coronary syndrome without persistent ST segment elevation; recommendations of the task force of the European Society of Cardiology. *Eur Heart J* 2000;21:1406-32.
- 4 Fox KA, Poole-Wilson P, Clayton TC, Henderson RA, Shaw TR, Wheatley DJ, et al. 5-year outcome of an interventional strategy in non-ST-elevation acute coronary syndrome: the British Heart Foundation RITA 3 randomised trial. *Lancet* 2005;366:914-20.
- 5 Lee KL, Woodlief LH, Topol EJ, Weaver WD, Betriu A, Col J, et al. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41,021 patients. GUSTO-I investigators. *Circulation* 1995;91:1659-68.
- 6 Morrow DA, Antman EM, Charlesworth A, Cairns R, Murphy SA, de Lemos JA, et al. TIMI risk score for ST-elevation myocardial infarction: a convenient, bedside, clinical score for risk assessment at presentation: an intravenous nPA for treatment of infarcting myocardium early II trial substudy. *Circulation* 2000;102:2031-7.
- 7 Morrow DA, Antman EM, Giugliano RP, Cairns R, Charlesworth A, Murphy SA, et al. A simple risk index for rapid initial triage of patients with ST-elevation myocardial infarction: an InTIME II substudy. *Lancet* 2001;358:1571-5.
- 8 Krumholz HM, Chen J, Wang Y, Radford MJ, Chen YT, Marciniak TA. Comparing AMI mortality among hospitals in patients 65 years of age and older: evaluating methods of risk adjustment. *Circulation* 1999;99:2986-92.
- 9 Boersma E, Pieper KS, Steyerberg EW, Wilcox RG, Chang WC, Lee KL, et al. Predictors of outcome in patients with acute coronary syndrome without persistent ST-segment elevation. Results from an international trial of 9461 patients. The PURSUIT investigators. *Circulation* 2000;101:2557-67.
- 10 Lindahl B, Toss H, Siegbahn A, Venge P, Wallentin L. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. *Frangmin during instability in coronary artery disease. N Engl J Med* 2000;343:1139-47.
- 11 Jollis JG. Measuring the effectiveness of medical care delivery. *J Am Coll Cardiol* 2001;37:998-1000.
- 12 Ohman EM, Granger CB, Harrington RA, Lee KL. Risk stratification and therapeutic decision making in acute coronary syndrome. *JAMA* 2000;284:876-8.
- 13 Granger CB, Goldberg RJ, Dabbous OM, Pieper KS, Eagle KA, Goodman SG, et al. Predictors of hospital mortality in the global registry of acute coronary events. *Arch Int Med* 2003;163:2345-53.
- 14 Eagle KA, Lim MJ, Dabbous OH, Pieper KS, Goldberg RJ, Van de Werf F, et al. A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. *JAMA* 2004;291:2727-33.
- 15 Van Domburg RT, van Miltenburg-van Zijl AJ, Veerhoek RJ, Simoons ML. Unstable angina: good long-term outcome after a complicated early course. *J Am Coll Cardiol* 1998;31:1534-9.
- 16 Cohen M, Antman EM, Murphy SA, Radley D. Mode and timing of treatment failure (recurrent ischemic events) after hospital admission for non-ST segment elevation acute coronary syndrome. *Am Heart J* 2002;143:63-9.
- 17 GRACE Investigators. Rationale and design of the GRACE (global registry of acute coronary events) project: a multinational registry of patients hospitalized with acute coronary syndrome. *Am Heart J* 2001;141:190-9.
- 18 Eagle KA, Goodman SG, Avezum A, Budaj A, Sullivan CM, Lopez-Sendon J. Practice variation and missed opportunities for reperfusion in ST-segment-elevation myocardial infarction: findings from the global registry of acute coronary events (GRACE). *Lancet* 2002;359:373-7.
- 19 Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndrome. The global use of strategies to open occluded coronary arteries (GUSTO) IIa Investigators. *Circulation* 1994;90:1631-7.
- 20 Killip T 3rd, Kimball JT. Treatment of myocardial infarction in a coronary care unit. A two year experience with 250 patients. *Am J Cardiol* 1967;20:457-64.
- 21 Guideline for the management of patients with acute coronary syndrome without persistent ECG ST segment elevation. British Cardiac Society Guidelines and Medical Practice Committee and Royal College of Physicians Clinical Effectiveness and Evaluation Unit. *Heart* 2001;85:133-42.
- 22 Grover SA, Lowensteyn I, Esrey KL, Steinert Y, Joseph L, Abrahamowicz M. Do doctors accurately assess coronary risk in their patients? Preliminary results of the coronary health assessment study. *BMJ* 1995;310:975-8.
- 23 McManus RJ, Mant J, Meulendijks CF, Salter RA, Pattison HM, Roalfe AK, et al. Comparison of estimates and calculations of risk of coronary heart disease by doctors and nurses using different calculation tools in general practice: cross sectional study. *BMJ* 2002;324:459-64.
- 24 Antman EM, Cohen M, Bernink PJ, McCabe CH, Horacek T, Papuchis G, et al. The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. *JAMA* 2000;284:835-42.
- 25 Savonitto S, Ardissino D, Granger CB, Morando G, Prando MD, Mafici A, et al. Prognostic value of the admission electrocardiogram in acute coronary syndrome. *JAMA* 1999;281:707-13.
- 26 Tu JV, Austin PC, Walld R, Roos L, Agran J, McDonald KM. Development and validation of the Ontario acute myocardial infarction mortality prediction rules. *J Am Coll Cardiol* 2001;37:992-7.
- 27 Jacobs DR Jr, Kroenke C, Crow R, Deshpande M, Gu DF, Gatewood L, et al. PREDICT: a simple risk score for clinical severity and long-term prognosis after hospitalization for acute myocardial infarction or unstable angina: the Minnesota heart survey. *Circulation* 1999;100:599-607.
- 28 Newby LK, Bhapkar MV, White HD, Topol EJ, Dougherty FC, Harrington RA, et al. Predictors of 90-day outcome in patients stabilized after acute coronary syndrome. *Eur Heart J* 2003;24:172-81.
- 29 De Araujo Goncalves P, Ferreira J, Aguiar C, Seabra-Gomes R. TIMI, PURSUIT, and GRACE risk scores: sustained prognostic value and interaction with revascularization in NSTE-ACS. *Eur Heart J* 2005;26:865-72.

doi 10.1136/bmj.38985.646481.55

Royal Infirmary of Edinburgh, University of Edinburgh, Edinburgh EH16 4SB

Keith A A Fox *British Heart Foundation professor of cardiology*

University of Massachusetts Medical School, Worcester, MA 01655, USA

Omar H Dabbous *statistician*

Robert J Goldberg *epidemiologist*

Frederick A Anderson Jr *research professor of surgery*

Duke Clinical Research Institute, Durham, NC 27705, USA

Karen S Pieper *statistician*

Christopher B Granger *cardiologist*

University of Michigan Cardiovascular Center, Ann Arbor, MI 48109-0477, USA

Kim A Eagle *cardiologist*

Universitair Ziekenhuis Gasthuisberg, Leuven, Belgium 3000

Frans Van de Werf *cardiologist*

Dante Pazzanese Institute of Cardiology, 04012-909 Sao Paulo, Brazil

Álvaro Avezum *cardiologist*

Terrence Donnelly Heart Centre, Division of Cardiology, St Michael's Hospital,

Toronto, ON, Canada M5B 1W8

Shaun G Goodman *cardiologist*

Royal Brompton and Harefield NHS Trust, Royal Brompton Hospital, London SW3 6NP

Marcus D Flather *cardiologist*

Correspondence to: K A A Fox [k.a.a.fox@ed.ac.uk](mailto:k.a.a.fox@ed.ac.uk)